Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

About Immune Pharmaceuticals

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMNP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.19
  • 50 Day Moving Average: $0.1941
  • 200 Day Moving Average: $0.2479
  • 52-Week Range: $131,291,000.00 - $0.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1.09
  • P/E Growth: 0.0000
  • Market Cap: $24.41M
  • Outstanding Shares: 131,291,000
  • Beta: 1.75
Profitability:
  • Return on Equity: -291.26%
  • Return on Assets: -64.25%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 0.07%
  • Quick Ratio: 0.07%
Additional Links:
Companies Related to Immune Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (1,513.77% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
DateFirmActionRatingPrice TargetDetails
11/3/2016FBR & CoReiterated RatingOutperform$3.00View Rating Details
5/16/2016Chardan CapitalReiterated RatingBuyView Rating Details
4/4/2016Roth CapitalReiterated RatingBuyView Rating Details
6/11/2015MLV & Co.Initiated CoverageBuy$6.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016        
8/16/2016Q2($0.13)($0.13)ViewN/AView Earnings Details
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details
11/12/2015Q315($0.18)($0.35)ViewListenView Earnings Details
8/17/2015Q215($0.22)($0.12)ViewN/AView Earnings Details
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details
4/15/2015($0.37)($0.34)ViewN/AView Earnings Details
8/14/2014($0.21)($0.27)ViewN/AView Earnings Details
5/22/2014($0.15)($0.35)ViewN/AView Earnings Details
4/11/2014($0.15)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
Current Year EPS Consensus Estimate: $-0.6200 EPS
Next Year EPS Consensus Estimate: $0.1700 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.14)($0.14)($0.14)
Q3 20162($0.14)($0.13)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Ownership Percentage: 6.74%
Institutional Ownership Percentage: 2.18%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Daniel KazadoDirectorBuy76,503$0.19$14,535.57View SEC Filing  
12/16/2016Daniel KazadoDirectorBuy161,377$0.19$30,661.63View SEC Filing  
8/4/2016Daniel Gedeon TeperCEOBuy937,500$0.38$356,250.00View SEC Filing  
8/4/2016Daniel KazadoDirectorBuy666,667$0.45$300,000.15View SEC Filing  
8/4/2016Monica E LuchiCMOBuy777,778$0.45$350,000.10View SEC Filing  
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
DateHeadline
finance.yahoo.com logoImmune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia (NASDAQ:IMNP)
finance.yahoo.com - February 17 at 5:32 PM
News IconStock Under Limelight: Immune Pharmaceuticals, Inc. (NASDAQ ... - The Oracle Examiner (NASDAQ:IMNP)
oracleexaminer.com - February 16 at 4:45 PM
News IconIs The Sell-Side Predicting That Immune Pharmaceuticals Inc. (NASDAQ:IMNP) Will Move Higher? - Winfield Review (NASDAQ:IMNP)
winfieldreview.com - February 16 at 4:45 PM
News IconAre Analysts Optimistic About Where Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is Heading? - Winfield Review (NASDAQ:IMNP)
winfieldreview.com - February 15 at 9:03 PM
istreetwire.com logoStocks Trend Analysis: Immune Pharmaceuticals, Inc. (IMNP), Ocwen Financial Corporation (OCN), Glu Mobile Inc ... - iStreetWire (NASDAQ:IMNP)
istreetwire.com - February 15 at 9:03 PM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMNP)
biz.yahoo.com - February 15 at 9:02 PM
News IconVolatile Stock Causing a Fracas Mid-Session: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Aiken Advocate (NASDAQ:IMNP)
aikenadvocate.com - February 13 at 6:56 PM
News IconFloating Price Update: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - StandardOracle (NASDAQ:IMNP)
standardoracle.com - February 13 at 11:14 AM
News IconImmune Pharmaceuticals, Inc. (NASDAQ:IMNP) Gapping Down Ahead of the Open - Aiken Advocate (NASDAQ:IMNP)
aikenadvocate.com - February 13 at 11:14 AM
News IconForward Earnings Estimate of Immune Pharmaceuticals Inc.(IMNP) - Highland Mirror (NASDAQ:IMNP)
www.highlandmirror.com - February 11 at 10:57 PM
News IconLet's Get Complex With Immune Pharmaceuticals, Inc. (IMNP) - Post Analyst (NASDAQ:IMNP)
postanalyst.com - February 9 at 4:41 AM
News IconTechnical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma (NASDAQ:IMNP)
www.kswo.com - February 7 at 7:10 PM
4-traders.com logoPfizer Inc. : Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares (NASDAQ:IMNP)
www.4-traders.com - February 6 at 10:36 AM
marketexclusive.com logoIMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:IMNP)
marketexclusive.com - February 4 at 10:56 PM
News IconImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Upgrades/Downgrades review - The Newburgh Press (NASDAQ:IMNP)
newburghpress.com - February 2 at 6:35 PM
News IconAt the Focal Point, Checking in on Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Prospect Journal (NASDAQ:IMNP)
prospectjournal.com - January 31 at 11:44 PM
istreetwire.com logoStocks Buzz: Immune Pharmaceuticals, Inc. (IMNP), MannKind ... - iStreetWire (NASDAQ:IMNP)
istreetwire.com - January 31 at 11:44 PM
News IconAre Insiders Bumping Up Their Positions in Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Wall Street Beacon (NASDAQ:IMNP)
wsbeacon.com - January 30 at 6:35 PM
News IconInvestor Focus on Technical Levels for Immune Pharmaceuticals Inc. (IMNP) - Sherwood Daily (NASDAQ:IMNP)
sherwooddaily.com - January 30 at 10:44 AM
News IconImmune Pharmaceuticals Inc (NASDAQ:IMNP) Wants A Partner - Insider Financial (NASDAQ:IMNP)
www.insiderfinancial.com - January 30 at 10:44 AM
istreetwire.com logoStocks Highlights: Immune Pharmaceuticals, Inc. (IMNP), Opko ... - iStreetWire (NASDAQ:IMNP)
istreetwire.com - January 28 at 12:55 AM
finance.yahoo.com logoImmune Pharmaceuticals Appoints New Chairman of the Board of Directors - Yahoo Finance (NASDAQ:IMNP)
finance.yahoo.com - January 28 at 12:55 AM
News IconChecking Out the Technicals for Immune Pharmaceuticals, Inc. (IMNP) - The USA Commerce (NASDAQ:IMNP)
theusacommerce.com - January 28 at 12:55 AM
News IconImmune Pharmaceuticals Appoints New Chairman of the Board of Directors (NASDAQ:IMNP)
www.di.se - January 27 at 5:39 AM
News IconTrading Spotlight: Zooming in on Shares of Immune Pharmaceuticals Inc. (IMNP) - Sherwood Daily (NASDAQ:IMNP)
sherwooddaily.com - January 26 at 7:36 PM
News IconTrading Sheet: Tracking Technicals for Immune Pharmaceuticals Inc. (IMNP) - Sherwood Daily (NASDAQ:IMNP)
sherwooddaily.com - January 24 at 6:38 PM
News IconImmune Pharmaceuticals Inc (NASDAQ:IMNP)'s Latest Deal Is Complimentary To Its's Portfolio - Insider Financial (NASDAQ:IMNP)
www.insiderfinancial.com - January 24 at 6:38 PM
4-traders.com logoiCo Therapeutics Inc : iCo Therapeutics Provides Multiple Corporate Updates (NASDAQ:IMNP)
www.4-traders.com - January 23 at 10:53 AM
streetinsider.com logoImmune Pharma (IMNP) Enters Exclusive Sub-License Agreement with SATT Sud-Est (NASDAQ:IMNP)
www.streetinsider.com - January 23 at 10:53 AM
finance.yahoo.com logoImmune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment (NASDAQ:IMNP)
finance.yahoo.com - January 23 at 10:53 AM
News IconImmune Pharmaceuticals, Inc. (NASDAQ:IMNP) shows monthly volitility of 8.47% - The Newburgh Press (NASDAQ:IMNP)
newburghpress.com - January 20 at 3:27 PM
News IconImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Bearish Target At $3 ... - Stock Observer (NASDAQ:IMNP)
www.thestockobserver.com - January 18 at 6:24 PM
News IconActive Trading Watch on Shares of Immune Pharmaceuticals Inc. (IMNP) - Sherwood Daily (NASDAQ:IMNP)
sherwooddaily.com - January 17 at 1:03 PM
News IconBargain Hunters Should Take a Look at Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Prospect Journal (NASDAQ:IMNP)
prospectjournal.com - January 17 at 1:03 PM
finance.yahoo.com logoImmune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI (NASDAQ:IMNP)
finance.yahoo.com - January 17 at 1:03 PM
News IconImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:IMNP)
www.thestockobserver.com - January 16 at 5:53 PM
News IconWill The Needle Move For Immune Pharmaceuticals Inc. (NASDAQ:IMNP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:IMNP)
wsbeacon.com - January 16 at 5:53 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Wall Street Beacon (NASDAQ:IMNP)
wsbeacon.com - January 16 at 8:37 AM
News IconCheap Stock Alert on Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Prospect Journal (NASDAQ:IMNP)
prospectjournal.com - January 16 at 8:37 AM
News IconTaking Aim at Shares of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Prospect Journal (NASDAQ:IMNP)
prospectjournal.com - January 14 at 12:10 AM
News IconImmune Pharmaceuticals Inc (NASDAQ:IMNP) To Request A Hearing For NASDAQ Compliance - Traders350 (NASDAQ:IMNP)
traders350.com - January 14 at 12:10 AM
News IconImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Quarterly EPS Set At $-0.11 - Stock Observer (NASDAQ:IMNP)
www.thestockobserver.com - January 13 at 7:08 PM
istreetwire.com logoStocks Buzz: American International Group, Inc. (AIG), Immune Pharmaceuticals, Inc. (IMNP), Bonanza Creek Energy ... - iStreetWire (NASDAQ:IMNP)
istreetwire.com - January 12 at 11:22 PM
News IconWarburton ready to relinquish Wales captaincy (NASDAQ:IMNP)
vouxmagazine.com - January 11 at 6:33 PM
News IconImmune Pharmaceuticals Inc (NASDAQ:IMNP): Here's Our Take - Insider Financial (NASDAQ:IMNP)
www.insiderfinancial.com - January 11 at 4:52 AM
finance.yahoo.com logo6:14 pm Immune Pharma will request an appeal to regain compliance with Nasdaq's minimum bid price rule (NASDAQ:IMNP)
finance.yahoo.com - January 9 at 11:40 PM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or (NASDAQ:IMNP)
biz.yahoo.com - January 9 at 6:39 PM
finance.yahoo.com logoImmune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule (NASDAQ:IMNP)
finance.yahoo.com - January 9 at 6:39 PM
News IconTesla Motors Inc (NASDAQ:TSLA) & Immune Pharmaceuticals Inc ... - MMA Ring Report (NASDAQ:IMNP)
mmaringreport.com - January 8 at 5:40 PM
News IconDaily Sentiment Score Of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) At 0.56 - Stock Observer (NASDAQ:IMNP)
www.thestockobserver.com - January 8 at 5:40 PM

Social

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

Where is Immune Pharmaceuticals' stock going? Where will Immune Pharmaceuticals' stock price be in 2017?

3 analysts have issued 1 year target prices for Immune Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Immune Pharmaceuticals' stock price to reach $3.00 in the next twelve months.

When will Immune Pharmaceuticals announce their earnings?

Immune Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November, 11th 2016.

How do I buy Immune Pharmaceuticals stock?

Shares of Immune Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immune Pharmaceuticals stock cost?

One share of Immune Pharmaceuticals stock can currently be purchased for approximately $0.19.

Immune Pharmaceuticals (NASDAQ:IMNP) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Earnings History Chart

Earnings by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Dividend History Chart

Dividend Payments by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Last Updated on 2/20/2017 by MarketBeat.com Staff